10 April 2024 - Migraine experts are advocating for PHARMAC to fund a new generation of migraine drugs that target neurotransmitters to transform the lives of those living with the neurological condition.

Acute medications which are taken at the start of a migraine attack and preventive medications which are taken to minimise the frequency and severity of migraine attacks are specifically developed for migraines and came with next to no side effects.

Migraine Foundation's lead researcher Dr Fiona Imlach told Breakfast in both acute and preventive treatments there are "not enough effective, safe treatments available to us at the moment".

She said the two injection treatments currently available in New Zealand are not funded by PHARMAC and are "not really well available".

Read One News article